A Study to Learn About Litfulo Capsule in People With Severe Alopecia Areata in Routine Clinical Practice.
KOREAN POST MARKETING SURVEILLANCE FOR LITFULO CAPSULE
In the register
The register attaches this trial to Ritlecitinib (Litfulo) (Pfizer), currently at “Approved” in the register. The programme's phase is checked by hand; the trial's is declared by its sponsor.
What the registry records
- Status
- Recruiting
- Declared phase
- No phase declared
- Sponsor
- Pfizer
- Participants (registry)
- 3000
- Start
- August 2025
- Primary completion
- March 2030 (planned)
- Study completion
- March 2030 (planned)
- Last registry update
- May 2026
- Countries
- South Korea
Conditions studied: Severe Alopecia Areata
Interventions: Litfulo, Ritlecitinib tosylate (ATC code: L04AF08)
Other trials of Ritlecitinib (Litfulo)
- NCT05522556Available (expanded access)
Pre-approval Single-patient Expanded Access for Ritlecitinib (PF-06651600)
- NCT07821216Active, not recruiting
Real-World Effectiveness of Ritlecitinib in Alopecia Areata Patients in the US: A Retrospective Analysis Using EHR and Claims Data
A Study in Young People and Adults to Learn About the Medicine Ritlecitinib for Treatment of Patchy Hair Loss, Known by the Medical Term as Moderate Alopecia Areata
- NCT07226531Completed
Utilization and Effectiveness of Ritlecitinib in a Real-World Population With Severe AA in the US
A Long-Term Study to Learn About The Study Medicine Called Ritlecitinib in Children With Severe Alopecia Areata.
A Study to Learn About Medicine Called Ritlecitinib in Children Aged Between 6 to 12 Years With Severe Alopecia Areata
A Study of 2 Doses of Ritlecitinib in People 12 Years of Age and Older With Alopecia Areata
- NCT07200128Completed
A Study to Learn About the Medicine Called Ritlecitinib in Adults With Severe Alopecia Areata in Real-world Settings
- NCT06531109Active, not recruiting
Characterization And Clinical Outcomes of AA Patients Treated With Ritlecitinib
- NCT06279221Active, not recruiting
Litfulo Capsules Special Investigation
A Study to Learn About the Study Medicine (Called Ritlecitinib) For the Potential Treatment of Severe Alopecia Areata (AA) In Children 6 To Less Than 12 Years of Age
Ritlecitinib for Cicatricial Alopecia
Listing a trial is not a recommendation to join one. Eligibility, risks and costs vary enormously — discuss any trial with your own doctor first. A registration proves a sponsor declared a study, not that it is progressing or will succeed. We're not doctors.